ARCUS BIOSCIENCS

 RCUSのチャート


 RCUSの企業情報

symbol RCUS
会社名 Arcus Biosciences Inc (ARCUS BIOSCIENCS)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 Arcus Biosciences Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on the discovery and development of cancer immunotherapy. Its pipeline includes AB928 AB680 AB122 and AB154. AB928 is a potent and selective dual antagonist of the adenosine receptors known as A2aR and A2bR.It is in the Phase-I clinical trial. AB680 is a potent and selective inhibitor of CD73 and is in the pre-clinical stage of development. AB122 is an anti-PD-1 antibody and is in the Phase-I dose-escalation trial. AB154 is a humanized anti-TIGIT antibody.  ア―カス・バイオサイエンシズは米国のバイオ医薬品企業。臨床段階で、がんに対し創造的で革新的な免疫治療の開発に従事する。同社は、科学的デ―タによって十分に特徴付けられた生物学的経路を標的とし、がんに対する免疫応答の調節の重要性に焦点を当てる。本社所在地はカリフォルニア州ヘイワ―ド。  Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1- 1.
本社所在地 3928 Point Eden Way Hayward CA 94545 USA
代表者氏名 Juan Carlos Jaen
代表者役職名 President Co-Founder
電話番号 +1 650-489-9000
設立年月日 42095
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 108人
url www.arcusbio.com
nasdaq_url
adr_tso
EBITDA (百万ドル) -51.19500
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 557.12770
売上高 (百万ドル) 8.35300
企業価値(EV) (百万ドル) 300.58370
当期純利益 (百万ドル) -49.59400
決算概要 BRIEF: For the fiscal year ended 31 December 2018 Arcus Biosciences Inc revenues increased from $1.4M to $8.4M. Net loss decreased 7% to $49.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest and other income net increase from $359K to $4.9M (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.27 to -$1.43.

 RCUSのテクニカル分析


 RCUSのニュース

   18 Stocks Moving in Tuesday''s Pre-Market Session  2022/04/05 11:28:24 Benzinga
Gainers System1, Inc. (NYSE: SST ) rose 37.5% to $22.70 in pre-market trading as the company reported a 48% year-over-year surge in Q4 sales and issued strong sales forecast. Recon Technology, Ltd. (NASDAQ: RCON ) rose 17.8% to $1.26 in pre-market trading following 13D filing from co-founder, Shenping Yin, showing raised stake in the company from 12% to 50%. Aterian, Inc. (NASDAQ: ATER ) rose 17.3% to $4.01 in pre-market trading after jumping around 47% on Monday. Patriot Transportation Holding, Inc. (NASDAQ: PATI ) rose 15.3% to $9.22 in pre-market trading. Arcus Biosciences, Inc. (NASDAQ: RCUS ) rose 13.1% to $39.47 in pre-market trading. Arcus Biosciences will replace Investors Bancorp in the S&P SmallCap 600 effective Thursday, April 7. Lilium N.V. (NASDAQ: LILM ) shares rose 13% to $5.49 in pre-market trading after jumping around 25% on Monday. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) shares rose 12.2% … Full story available on Benzinga.com
   Arcus Biosciences gains 10% on addition to SmallCap 600  2022/04/04 21:26:18 Seeking Alpha
Arcus Biosciences (RCUS) has jumped 9.7% postmarket on the news it''s set to join the S&P SmallCap 600 index
   Arcus Biosciences Set to Join S&P SmallCap 600  2022/04/04 21:15:00 S&P Global Platts
NEW YORK, April 4, 2022: Arcus Biosciences Inc. (NYSE:RCUS) will replace Investors Bancorp Inc. (NASD:ISBC) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, April 7. S&P 500 constituent Citizens Financial Group Inc. (NYSE: CFG) is acquiring Investors Bancorp in a deal expected to be completed soon pending final closing conditions.
   Arcus Biosciences Inc. (NYSE: RCUS) Down -5.51%: This Is What Analysts Now Expect  2022/04/01 15:30:00 Stocks Register
Arcus Biosciences Inc. (NYSE:RCUS) shares, rose in value on Thursday, 03/31/22, with the stock price down by -5.51% to the previous day’s close as strong demand from buyers drove the stock to $31.56. Actively observing the price movement in the last trading, the stock closed the session at $33.40, falling within a range of $31.26 … Arcus Biosciences Inc. (NYSE: RCUS) Down -5.51%: This Is What Analysts Now Expect Read More »
   Global Metastatic Colorectal Cancer Market Research Report 2022: Comprehensive Insights About 140+ Companies and 140+ Pipeline Drugs - ResearchAndMarkets.com  2022/03/10 17:40:00 Benzinga
The "Metastatic Colorectal cancer - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com''s offering. The publisher''s, "Metastatic Colorectal cancer - Pipeline Insight, 2022," report provides comprehensive insights about 140+ companies and 140+ pipeline drugs in Metastatic Colorectal cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. A detailed picture of the Metastatic Colorectal cancer pipeline landscape is provided which includes the disease overview and Metastatic Colorectal cancer treatment guidelines. The assessment part of the report embraces, in depth Metastatic Colorectal cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Colorectal cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
   Arcus Biosciences GAAP EPS of $3.71 beats by $4.33, revenue of $354.5M beats by $305.07M  2022/02/23 22:49:14 Seeking Alpha
Arcus Biosciences press release (RCUS): Q4 GAAP EPS of $3.71 beats by $4.33.Revenue of $354.5M (+3635.5% Y/Y) beats by $305.07M.“Arcus is starting 2022 with a strong cash position…
   Arcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update  2022/02/23 21:05:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update on its six clinical-stage molecules targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a and PD-1 across common cancers, including lung
   Octagon Capital Advisors LP Buys Arcus Biosciences Inc, ITeos Therapeutics Inc, Apellis ...  2022/02/19 04:38:29 GuruFocus
Related Stocks: RCUS , APLS , BBIO , FDMT , IMAB , STOK , ITOS , KROS , KDNY , IMVT , OLMA , CMPX , CRIS , ISEE , NGM , IKNA , PMVP , EWTX ,
   Arcus Biosciences grants employees options to buy ~39K shares  2022/01/25 21:32:25 Seeking Alpha
Arcus Biosciences (RCUS) granted six new employees options to buy a total of 38,850 common shares at $31.75 apiece and restricted stock units to acquire a total of 925 shares.The…
   Hedge Funds Are Selling Arcus Biosciences, Inc. (RCUS)  2022/01/14 16:42:34 Insider Monkey
While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending, many smart money investors are starting to get cautious
   Arcus Biosciences GAAP EPS of $3.71 beats by $4.33, revenue of $354.5M beats by $305.07M  2022/02/23 22:49:14 Seeking Alpha
Arcus Biosciences press release (RCUS): Q4 GAAP EPS of $3.71 beats by $4.33.Revenue of $354.5M (+3635.5% Y/Y) beats by $305.07M.“Arcus is starting 2022 with a strong cash position…
   Arcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update  2022/02/23 21:05:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update on its six clinical-stage molecules targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a and PD-1 across common cancers, including lung
   Octagon Capital Advisors LP Buys Arcus Biosciences Inc, ITeos Therapeutics Inc, Apellis ...  2022/02/19 04:38:29 GuruFocus
Related Stocks: RCUS , APLS , BBIO , FDMT , IMAB , STOK , ITOS , KROS , KDNY , IMVT , OLMA , CMPX , CRIS , ISEE , NGM , IKNA , PMVP , EWTX ,
   Arcus Biosciences grants employees options to buy ~39K shares  2022/01/25 21:32:25 Seeking Alpha
Arcus Biosciences (RCUS) granted six new employees options to buy a total of 38,850 common shares at $31.75 apiece and restricted stock units to acquire a total of 925 shares.The…
   Hedge Funds Are Selling Arcus Biosciences, Inc. (RCUS)  2022/01/14 16:42:34 Insider Monkey
While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending, many smart money investors are starting to get cautious

 関連キーワード  (医薬品 米国株 ARCUS BIOSCIENCS RCUS )

 twitter  (公式ツイッターやCEOツイッターなど)